To Assess the Safety and Tolerability of 7.5, 15 and 30 mg of Sublingual Lobeline. - 1

National Institutes of Health (NIH)

Status and phase: Unknown; Phase 1

Conditions: Amphetamine-Related Disorders

Treatments: Drug: Lobeline

Study type: Interventional

Funder types: NIH

Identifiers

NCT00100074

NIDA-CPU-0007-1

Details and patient eligibility

About

To assess the safety and tolerability of 7.5, 15 and 30 mg of sublingual lobeline.

Full description

The primary objective of this study is to characterize the pharmacokinetics of three ascending doses of lobeline in normal volunteers.

Sex: All

Ages: 18 to 45 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy individuals with a body mass index between 18 and 30.
• Willing and able to give written consent.
• Must have a negative drug test
• Females must have a negative pregnancy test prior to study drug administration
• Must have no medical contraindications as determined by routine testing

Exclusion criteria

• Please contact the site for more information